PortfoliosLab logoPortfoliosLab logo
SYRE vs. RVMD
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SYRE vs. RVMD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spyre Therapeutics Inc. (SYRE) and Revolution Medicines, Inc. (RVMD). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SYRE achieves a 206.23% return, which is significantly higher than RVMD's 108.17% return.


SYRE

1D
13.56%
1M
35.48%
YTD
206.23%
6M
193.33%
1Y
568.35%
3Y*
115.67%
5Y*
-9.28%
10Y*
-2.85%

RVMD

1D
1.73%
1M
9.40%
YTD
108.17%
6M
105.77%
1Y
318.08%
3Y*
86.60%
5Y*
38.23%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

SYRE vs. RVMD - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
SYRE
Spyre Therapeutics Inc.
206.23%40.72%8.18%91.33%-90.53%-39.64%-7.19%
RVMD
Revolution Medicines, Inc.
108.17%82.10%52.51%20.40%-5.36%-36.42%40.34%

Correlation

The correlation between SYRE and RVMD is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.35

Correlation (3Y)
Calculated over the trailing 3-year period

0.37

Correlation (5Y)
Calculated over the trailing 5-year period

0.30

Correlation (All Time)
Calculated using the full available price history since Feb 13, 2020

0.30

Fundamentals

Market Cap

SYRE:

$34.72B

RVMD:

$32.85B

EPS

SYRE:

-$0.88

RVMD:

-$7.17

PB Ratio

SYRE:

66.20

RVMD:

21.90

Total Revenue (TTM)

SYRE:

$90.49M

RVMD:

$0.00

Gross Profit (TTM)

SYRE:

$0.00

RVMD:

-$4.70M

EBITDA (TTM)

SYRE:

-$171.29M

RVMD:

-$1.34B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SYRE vs. RVMD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SYRE
SYRE Risk / Return Rank: 9999
Overall Rank
SYRE Sharpe Ratio Rank: 100100
Sharpe Ratio Rank
SYRE Sortino Ratio Rank: 9999
Sortino Ratio Rank
SYRE Omega Ratio Rank: 9898
Omega Ratio Rank
SYRE Calmar Ratio Rank: 100100
Calmar Ratio Rank
SYRE Martin Ratio Rank: 100100
Martin Ratio Rank

RVMD
RVMD Risk / Return Rank: 9898
Overall Rank
RVMD Sharpe Ratio Rank: 9898
Sharpe Ratio Rank
RVMD Sortino Ratio Rank: 9999
Sortino Ratio Rank
RVMD Omega Ratio Rank: 9898
Omega Ratio Rank
RVMD Calmar Ratio Rank: 9898
Calmar Ratio Rank
RVMD Martin Ratio Rank: 9898
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SYRE vs. RVMD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Spyre Therapeutics Inc. (SYRE) and Revolution Medicines, Inc. (RVMD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


SYRERVMDDifference
Sharpe ratioReturn per unit of total volatility

+3.58

Sortino ratioReturn per unit of downside risk

+0.48

Omega ratioGain probability vs. loss probability

1.74

1.82

-0.08

Calmar ratioReturn relative to maximum drawdown

34.16

12.84

+21.31

Martin ratioReturn relative to average drawdown

95.79

30.76

+65.02

SYRE vs. RVMD - Sharpe Ratio Comparison

The current SYRE Sharpe Ratio is 8.35, which is higher than the RVMD Sharpe Ratio of 4.77. The chart below compares the historical Sharpe Ratios of SYRE and RVMD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

SYRE vs. RVMD - Drawdown Comparison

The maximum SYRE drawdown since its inception was -99.11%, which is greater than RVMD's maximum drawdown of -73.29%. Use the drawdown chart below to compare losses from any high point for SYRE and RVMD.


Loading charts...

Drawdown Indicators


SYRERVMDDifference

Max Drawdown

Largest peak-to-trough decline

-99.11%

-73.29%

-25.82%

Max Drawdown (1Y)

Largest decline over 1 year

-16.79%

-24.95%

+8.16%

Max Drawdown (3Y)

Largest decline over 3 years

-73.99%

-48.63%

-25.36%

Max Drawdown (5Y)

Largest decline over 5 years

-98.74%

-56.85%

-41.89%

Max Drawdown (10Y)

Largest decline over 10 years

-99.04%

Current Drawdown

Current decline from peak

-66.53%

0.00%

-66.53%

Average Drawdown

Average peak-to-trough decline

-62.69%

-35.58%

-27.11%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.98%

10.40%

-4.42%

Volatility

SYRE vs. RVMD - Volatility Comparison

Spyre Therapeutics Inc. (SYRE) has a higher volatility of 20.51% compared to Revolution Medicines, Inc. (RVMD) at 14.01%. This indicates that SYRE's price experiences larger fluctuations and is considered to be riskier than RVMD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SYRERVMDDifference

Volatility (1M)

Calculated over the trailing 1-month period

20.51%

14.01%

+6.50%

Volatility (6M)

Calculated over the trailing 6-month period

47.36%

55.27%

-7.91%

Volatility (1Y)

Calculated over the trailing 1-year period

68.82%

67.30%

+1.52%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

179.28%

62.57%

+116.71%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

136.27%

65.69%

+70.58%

Dividends

SYRE vs. RVMD - Dividend Comparison

Neither SYRE nor RVMD has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

SYRE vs. RVMD - Financials Comparison

This section allows you to compare key financial metrics between Spyre Therapeutics Inc. and Revolution Medicines, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M2022202320242025202600
(SYRE) Total Revenue
(RVMD) Total Revenue
Values in USD except per share items

Frequently Asked Questions


SYRE and RVMD have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SYRE has higher volatility (20.51%) compared to RVMD (14.01%). In terms of maximum drawdown, SYRE dropped -99.11% vs RVMD's -73.29%.

SYRE currently has the higher Sharpe Ratio (8.35 vs 4.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SYRE and RVMD

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer